Observational studyJornal brasileiro de nefrologia
IL-18 on the rise: tracking inflammatory drift in hemodialysis patients - a pilot study.
Observational study in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInterleukin-18 (IL-18) is a pro-inflammatory cytokine associated with inflammaging and cellular senescence in chronic kidney disease (CKD).
objectiveTo evaluate longitudinal changes in plasma IL-18 levels in incident hemodialysis (HD) patients.
methodsAn observational longitudinal study was conducted, with blood and anthropometric data collected at baseline, 6, and 12 months. IL-18 was measured by ELISA, and biochemical parameters were measured using Bioclin® kits.
resultsTwenty-four patients (61.4 ± 3.5 years) were enrolled; 10 and 5 completed the 6- and 12-month assessments, respectively. IL-18 levels increased significantly at 6 months (p = 0.04) and at 12 months (p = 0.01) versus baseline and correlated positively with creatinine (r = 0.893; p = 0.04) and urea (r = 0.823; p = 0.05).
conclusionIn this pilot study with incident HD patients, plasma IL-18 increased over one year of treatment and was associated with uremia-related markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.